Cancer

Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer

WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) --  Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced…

1 month ago

Life Line Screening (Updated): What You Need to Know?

New York City,, Jan. 01, 2026 (GLOBE NEWSWIRE) -- in 2026, The greatest way to stay healthy and avoid illnesses…

1 month ago

Heal N Soothe (Updated): Does It Work For Chronic Pain?

New York City,, Jan. 01, 2026 (GLOBE NEWSWIRE) -- In 2026, Millions of people suffer from chronic back and joint…

1 month ago

XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update

Clinical Data doubles known genetic factors associated with urate and GoutCALGARY, Alberta, Dec. 31, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics…

1 month ago

Alvotech Secures Term Loan Facility of USD 100 Million

USD 100 million senior term loan facility with a 2-year maturityStrengthens liquidity to support execution across Alvotech’s R&D pipeline and…

1 month ago

Alvotech Secures Term Loan Facility of USD 100 Million

USD 100 million senior term loan facility with a 2-year maturityStrengthens liquidity to support execution across Alvotech’s R&D pipeline and…

1 month ago

Izotropic Announces AGM Results

Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - December 31, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3)…

1 month ago

Establishment Labs to Present at 44th Annual J.P. Morgan Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness,…

1 month ago

FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis

HOUSTON, Dec. 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued…

1 month ago

Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders

TARPON SPRINGS, Fla., December 31, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical…

1 month ago